The Sam Rothberg Glaucoma Center, Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Graefes Arch Clin Exp Ophthalmol. 2021 May;259(5):1253-1262. doi: 10.1007/s00417-021-05091-6. Epub 2021 Feb 2.
Despite advances in glaucoma treatment options, patient adherence and compliance remain very low. The EyePhone© App is a free non-commercial reminder application designed specifically for the needs of glaucoma patients. In this study, we evaluated its usefulness in improving adherence to medical treatment among glaucoma patients.
This is a prospective multicenter interventional study. Glaucoma patients were recruited from a tertiary center and a large community glaucoma service center. After a short explanation, the EyePhone© App was installed on their smartphone device, and the notifications for the current medical treatment were entered. After enrollment and at 1-month follow-up, subjects completed the Morisky Medication Adherence Scale (MMAS-8) and the Quality of Life and Glaucoma 17-item (GlauQOL-17) questionnaires for evaluation of adherence and QOL, respectively.
In the study, 133 patients (71 men and 62 women) aged 62±15.5 years and using 2.0±0.9 IOP-lowering drugs participated. The proportion of highly adherent subjects improved from 29.3% (39/133) at baseline to 42.1% (56/133) at follow-up (P < 0.001), and the proportion of poorly adherent subjects decreased from 29.3 (39/133) to 20.3% (27/133) at follow-up (P = 0.012). QOL also improved, as evidenced by a significant increase in the GlauQOL-17 score (P < 0.05). In a subgroup of patients for whom IOP measurements were available, IOP reduced by 0.92 mmHg (P = 0.069).
Significant improvements in glaucoma adherence and QOL were achieved among poorly adherent glaucoma patients after 1 month of using the EyePhone© App.
尽管青光眼治疗选择有所进步，但患者的依从性和顺应性仍然很低。EyePhone©应用程序是一款免费的非商业性提醒应用程序，专为青光眼患者的需求而设计。在这项研究中，我们评估了它在提高青光眼患者药物治疗依从性方面的有用性。
这是一项前瞻性多中心干预研究。从一家三级中心和一家大型社区青光眼服务中心招募青光眼患者。在简短解释后，将 EyePhone©应用程序安装在他们的智能手机设备上，并输入当前药物治疗的通知。入组后和 1 个月随访时，受试者分别完成了 Morisky 药物依从性量表（MMAS-8）和生活质量和青光眼 17 项（GlauQOL-17）问卷，以评估依从性和生活质量。
研究中，133 名患者（71 名男性和 62 名女性）年龄 62±15.5 岁，使用 2.0±0.9 种降眼压药物。高度依从性患者的比例从基线时的 29.3%（39/133）提高到随访时的 42.1%（56/133）（P<0.001），依从性差的患者比例从 29.3%（39/133）下降到随访时的 20.3%（27/133）（P=0.012）。生活质量也有所改善，GlauQOL-17 评分显著提高（P<0.05）。在可获得眼压测量值的患者亚组中，眼压降低了 0.92mmHg（P=0.069）。
在使用 EyePhone©应用程序 1 个月后，依从性差的青光眼患者的青光眼依从性和生活质量显著提高。
